Jade Biosciences, Inc.
JBIO
$15.35
$0.130.85%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 7.39M | 6.44M | 5.39M | 5.23M | 3.36M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 43.45M | 34.98M | 27.40M | 27.78M | 23.38M |
| Operating Income | -43.45M | -34.98M | -27.40M | -27.78M | -23.38M |
| Income Before Tax | -40.35M | -31.87M | -25.18M | -32.13M | -38.17M |
| Income Tax Expenses | 16.00K | 58.00K | -- | -- | -- |
| Earnings from Continuing Operations | -40.37M | -31.93M | -25.18M | -32.13M | -38.17M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -40.37M | -31.93M | -25.18M | -32.13M | -38.17M |
| EBIT | -43.45M | -34.98M | -27.40M | -27.78M | -23.38M |
| EBITDA | -43.44M | -34.97M | -27.39M | -27.78M | -- |
| EPS Basic | -0.57 | -0.50 | -0.48 | -0.86 | -12.10 |
| Normalized Basic EPS | -0.44 | -0.37 | -0.40 | -0.57 | -4.51 |
| EPS Diluted | -0.57 | -0.50 | -0.48 | -0.86 | -12.10 |
| Normalized Diluted EPS | -0.44 | -0.37 | -0.40 | -0.57 | -4.51 |
| Average Basic Shares Outstanding | 57.78M | 53.99M | 39.58M | 28.43M | 3.16M |
| Average Diluted Shares Outstanding | 57.78M | 53.99M | 39.58M | 28.43M | 3.16M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |